Clinical Trial Update: Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension [Phase 3]

View source ↗

Summary

Phase 3 trial comparing olmesartan/HCTZ 40/12.5 mg combination therapy to olmesartan monotherapy in essential hypertension has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Olmesartan Medoxomil 40 mg (olmesartan medoxomil)
• Olmesartan/Hydrochlorothiazide 40/12.5 mg (olmesartan medoxomil plus hydrochlorothiazide)

Snippet

Sponsor: Menarini Group | Conditions: Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2021-07-28